stockportfolio.pro
HUTCHMED (China) Limited (HCM)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
HUTCHMED (China) Limited revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $426.41M | $838.00M | $630.20M | $548.51M |
| Gross profit | $115.31M | $453.55M | $281.32M | $212.16M |
| Net income | $-360.83M | $100.78M | $37.73M | $456.91M |
| Net margin | -84.6% | 12.0% | 6.0% | 83.3% |
Source: HUTCHMED (China) Limited SEC filings (10-K).
Explore 4 years of HUTCHMED (China) Limited financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track HCM in your portfolio →
HUTCHMED (China) Limited financial history by metric
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
HUTCHMED (China) Limited — frequently asked questions
What is HUTCHMED (China) Limited's revenue?
HUTCHMED (China) Limited (HCM) reported revenue of $548.51M for fiscal year 2025, down 13.0% from the prior year, according to its SEC filings.
Is HUTCHMED (China) Limited profitable?
Yes. HCM earned net income of $456.91M in fiscal 2025, a net margin of 83.3%.
What is HCM's P/E ratio?
HUTCHMED (China) Limited trades at a price-to-earnings ratio of about 4.0 based on the latest data in our nightly-refreshed cache.
How fast is HUTCHMED (China) Limited growing?
HCM's revenue grew at roughly 8.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does HUTCHMED (China) Limited have?
As of fiscal year 2025, HCM carried roughly $93.16M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is HUTCHMED (China) Limited's gross margin?
HCM's gross margin was 38.7% in fiscal 2025 — gross profit of $212.16M on revenue of $548.51M.
What is HUTCHMED (China) Limited's market cap?
HUTCHMED (China) Limited (HCM) has a market capitalization of about $1.84B, based on the latest data in our nightly-refreshed cache.
When does HUTCHMED (China) Limited's fiscal year end?
HCM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from HUTCHMED (China) Limited's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.